ProCE Banner Activity

Phase Ib/II ECHO-202/KEYNOTE-037: Epacadostat + Pembrolizumab in Pts With Advanced Urothelial Carcinoma

Slideset Download
Conference Coverage
In patients with advanced urothelial carcinoma, epacadostat plus pembrolizumab well tolerated, with ORR of 35% (DCR: 53%) in this patient cohort.

Released: June 14, 2017

Expiration: June 13, 2018

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants by

AbbVie

Amgen, Inc.

AstraZeneca

Celgene

Genentech Roche Virology

Halozyme

Incyte

Merck Oncology